Latest News — Page 11

Could a UCT licence kick-start local medical device manufacturing? 🏭⚕️

A recent UCT licensing agreement paves the way for domestic production of essential medical devices, cutting import dependence, lowering costs, boosting supply-chain resilience and creating skilled jobs — all while clarifying regulatory and quality expectations.

Read the full article to learn what the licence covers, who stands to benefit, and next steps for scaling local production.

#SyenzaNews #medicaldevices #MedTech #innovation #MarketAccess

Are formulary changes finally widening access to GLP‑1 therapies? 💊📈

Recent formulary updates are expanding payer coverage and easing utilization controls for GLP‑1 medications, reshaping access for diabetes and obesity care while driving new budget, clinical-pathway, and manufacturer strategy implications.

Read the full article to see the specific formulary shifts, what they mean for payers, providers, and manufacturers, and how to prepare for the evolving market.

#SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #healthcarepolicy

🔍 Can comparative effectiveness research (CER) make drug pricing fairer and more evidence-driven?

This article explains how integrating CER into pricing frameworks can align prices with real-world value, improve payer decision-making, and support sustainable access—while outlining practical policy and methodological steps to get there.

Read the full piece to see actionable recommendations for policymakers, payers, and manufacturers. ➡️

#SyenzaNews #HealthEconomics #pharmaceuticals #MarketAccess #costeffectiveness

Are European pharmacists ready to be the frontline of the next health crisis? 🛡️

From expanded vaccination and testing roles to strengthened supply‑chain coordination and targeted emergency training, pharmacists across Europe are being equipped and empowered to ease hospital burden and improve community resilience. This shift highlights practical policy changes, digital tools, and collaborative frameworks that make pharmacy-led response more effective.

Read the full article to see what’s changing and how healthcare systems can leverage pharmacists in future crises.

#SyenzaNews #pharmaceuticals #HealthcareInnovation #healthcarepolicy #innovation

Could Imfinzi redefine treatment options for bladder cancer? 🔬

Imfinzi’s recent approval is an important immunotherapy milestone for urothelial carcinoma, bringing a new, clinically supported option with a manageable safety profile. This decision could reshape clinical pathways and market-access discussions across oncology stakeholders.

Read the full article to understand the clinical evidence, patient impact, and what this means for clinicians, payers, and future drug development.

#SyenzaNews #oncology #pharmaceuticals #innovation #MarketAccess

Could radioligand therapy be a game-changer for advanced prostate cancer? 🔬

Recent advances in PSMA-targeted radioligand therapies are showing improved clinical outcomes and a more precise approach to treating metastatic prostate cancer, while highlighting important considerations around regulatory approval, manufacturing, and payer access.

Read the full article to explore the latest trial data, implementation challenges, and what these developments mean for clinicians, patients, and industry.

#SyenzaNews #oncology #precisionmedicine #innovation #MarketAccess

Could AI chatbots be the scalable frontline for mental healthcare? 💬🤖

This article summarizes evidence that conversational agents can deliver CBT-style support, improve access and engagement, and produce symptom improvements for some users — while flagging key concerns around privacy, safety, personalization, and clinician integration.

Read the full article for practical guidance on effectiveness, implementation pitfalls, and best practices for responsibly deploying conversational-agent interventions in mental health.

#SyenzaNews #digitalhealth #AIinHealthcare #ai #innovation

Can a single new building accelerate biomedical breakthroughs in Coimbra? 🔬🚀

UC Biomed’s investment in a state-of-the-art facility brings cutting-edge labs, shared core equipment, and collaborative spaces designed to fast-track translational research, industry partnerships, and commercialization. This strategic boost positions Coimbra as a growing hub for life‑science talent and regional innovation.

Read the full article to see how the project could reshape research, industry collaboration, and local economic growth.

#SyenzaNews #biotechnology #HealthcareInnovation #innovation #strategicplanning

Who won the Health Innovation Award 2026 — and what their solutions mean for sustainable healthcare 🏆🌱

This piece highlights the winning innovations that cut carbon, reduce waste, and improve system resilience — from energy-efficient facilities and circular supply models to digital tools that streamline care delivery and lower footprint. It also outlines funding, scaling strategies, and policy levers helping these solutions move from pilots to system-wide impact.

Read the full article to meet the winners and learn practical steps health leaders can take to scale sustainable innovation.

#SyenzaNews #HealthcareInnovation #HealthTech #innovation #healthcarepolicy

Can Portugal’s latest health strategy deliver sustainable, system-wide change? 🇵🇹♻️

The government is focusing on prevention, stronger primary care, digital health adoption and sustainable financing to boost access, resilience and equity across the system. This article outlines the concrete commitments, implementation milestones and the trade-offs health leaders should expect.

Read the full piece to see what these reforms mean for providers, payers and policymakers — and which indicators will show early progress.

#SyenzaNews #healthcare #HealthcareInnovation #healthcarepolicy #strategicplanning

Is Europe ready for the next health emergency? 🌍🛡️

This piece outlines how strengthened surveillance, supply‑chain resilience, and cross‑border coordination can boost European health preparedness amid rising geopolitical tensions and constrained resources. It also offers policy recommendations and practical steps for governments and health systems to improve readiness.

Read the full analysis to see actionable strategies for policymakers and health leaders.

#SyenzaNews #globalhealth #healthcare #strategicplanning #healthcarepolicy

🚨 Are unregistered GLP‑1/GIP products putting patients at risk?

SAHPRA and the SAPC have stepped up enforcement, highlighting safety, legal and supply‑chain risks tied to unregistered incretin therapies. This article summarizes recent actions, how to verify product registration, and practical steps pharmacies, prescribers and distributors should take to stay compliant and protect patients.

Read the full article for details and an actionable compliance checklist.

#SyenzaNews #regulatoryaffairs #pharmaceuticals #governance #healthcarepolicy

Is your MedTech roadmap keeping pace with new MDR rules for software?

This article breaks down the latest MDR and SaMD guidance — from clinical evidence and cybersecurity expectations to post-market surveillance and notified-body capacity — and explains the compliance risks, timeline impacts, and where clearer rules create opportunities for product differentiation.

Read the full piece for practical steps and a strategic checklist to future‑proof your software medical devices. 🔍🚀

#SyenzaNews #MedTech #regulatoryaffairs #innovation #DigitalTransformation

Could a GBA-targeted therapy reshape Parkinson’s treatment? 🔬

The completion of the ACTIVATE study is a major milestone for GBA-PD drug development — providing key safety and biomarker data that support progression to later-stage trials and clearer go-to-market planning.

Read the full article to learn what the results mean for patients, developers, and payers.

#SyenzaNews #drugdevelopment #clinicaltrials #innovation #MarketAccess

Could wearables finally transform menstrual health monitoring? ⌚📈

Wearable sensors are delivering continuous physiological data that enable personalized cycle mapping, fertility insights, and better symptom management for users — while also offering valuable, de-identified data for clinicians and researchers. The article highlights market opportunities, validation and privacy challenges, and regulatory considerations companies and health systems must address to scale trustworthy, evidence-based solutions.

Read the full article for practical takeaways and strategic implications for developers, clinicians, and investors.

#SyenzaNews #digitalhealth #HealthTech #DigitalTransformation #innovation

Could CHMP’s opinion on Keytruda and Padcev reshape perioperative care for bladder cancer? 🔬

A CHMP recommendation now highlights expanded perioperative use of pembrolizumab (Keytruda) and enfortumab vedotin (Padcev) for muscle‑invasive bladder cancer, signaling new neoadjuvant/adjuvant options that could lower recurrence risk and change treatment pathways.

Read the full article for the trial evidence, regulatory next steps, and what this means for clinicians, payers, and patients.

#SyenzaNews #oncology #pharmaceuticals #MarketAccess #innovation